University of Adelaide affiliated researchers have made significant advances in developing a novel vaccine against Zika virus. The vaccine candidate could possibly lead to global eradication of the disease. A breakthrough, it is the first T-cell based investigational Zika vaccine. The team has more preclinical research left to ready for the right clinical trials partner to then commercialize.
The Australian-based virology team, led by Professor Eric Gowans and Dr. Branka Grubor-Bauk from the Basil Hetzel Institute for Translational Health Research, and supported by the Hospital Research Foundation—has developed a vaccine that the team reports prevents Zika infection in pre-clinical models of the disease. The team’s recent findings are now published in the international journal Science Advance.
What is Zika?
A mosquito-transmitted ‘flavivirus’ that can cause microcephaly (a birth defect where a baby’s head is significantly smaller than expected) and severe birth defects in infants born to infected mothers. Hence, the introduction of a successful Zika vaccine could help prevent infection of pregnant women and the resultant congenital effects in the unborn chil...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).